Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study

References

• Bylund S, Kobyletzki LB, Svalstedt M, et al. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. doi: 10.2340/00015555-3510
   PubMed Web of Science ®Google Scholar
• Gori N, Chiricozzi A, Marsili F, et al. National information campaign revealed disease characteristic and burden in adult patients suffering from atopic dermatitis. J Clin Med. 2022;11(17):5204. doi: 10.3390/jcm11175204
   PubMed Web of Science ®Google Scholar
• Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy. 2021;76(4):1053–1076. doi: 10.1111/all.14631
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. First update of the living European guideline (EuroGuiderm) on atopic eczema. J Eur Acad Dermatol Venereol. 2023;37(11):e1283–7. doi: 10.1111/jdv.19269
   PubMed Web of Science ®Google Scholar
• Gori N, Sernicola A, Tolino E, et al. Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study. J DermatolTreat. 2023;34(1):2230685. doi: 10.1080/09546634.2023.2230685
   Google Scholar
• Chiricozzi A, Gori N, Maurelli M, et al. Biological agents targeting interleukin-13 for atopic dermatitis. Expert Opin Biol Ther. 2022;22(5):651–659. doi: 10.1080/14712598.2022.2035356
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Adam DN, Zirwas M, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23(4):547–559. doi: 10.1007/s40257-022-00702-2
   PubMed Web of Science ®Google Scholar
• Gutermuth J, Pink AE, Worm M, et al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440–52. doi:10.1111/bjd.20832
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J DermatolTreat. 2023;34(1):2216815. doi: 10.1080/09546634.2023.2216815
   Google Scholar
• Pezzolo E, Schena D, Gambardella A, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. [2023 Jul 22]. Online ahead of print. doi: 10.1111/jdv.19382
   Web of Science ®Google Scholar
• Pereyra-Rodríguez JJ, Herranz P, Ruiz-Villaverde R, et al. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: Short-term effectiveness and safety results. Clin Exp Dermatol. 2023;48(9):991–997. doi: 10.1093/ced/llad153
   PubMedGoogle Scholar
• De Greef A, Ghislain PD, Bulinckx A, et al. Real-life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: a multicentric prospective study. Clin Drug Investig. 2023;43(4):299–306. doi: 10.1007/s40261-023-01258-7
   PubMed Web of Science ®Google Scholar
• Bruin-Weller M D, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: An international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402. doi: 10.2340/00015555-3751
   PubMedGoogle Scholar
• Bruin-Weller M D, Deleuran M, Biedermann T, et al. The treat-to-target project in atopic dermatitis: One year on. Acta Derm Venereol. 2023;103:adv5382. doi: 10.2340/actadv.v103.5382
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Gori N, Di Nardo L, et al. Therapeutic impact and management of Persistent head and neck atopic dermatitis in dupilumab-treated patients. Dermatology. 2022;238(4):717–724. doi: 10.1159/000519361
   PubMed Web of Science ®Google Scholar
• Gori N, Ippoliti E, Peris K, et al. Head and neck atopic dermatitis: Still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23(7):575–577. doi:10.1080/14712598.2023.2224499
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China. J Eur Acad Dermatol Venereol. 2020;34(10):2346–2352. doi: 10.1111/jdv.16346
   PubMed Web of Science ®Google Scholar
• Merola JF, Butler DC, Mark T, et al. Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: A secondary analysis. JAMA Dermatol. 2023;159(10):1119–1123. doi:10.1001/jamadermatol.2023.2626
   PubMed Web of Science ®Google Scholar
• Thaçi D, Kleinheinz A, Anastasiadou DM, et al. A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): Baseline characteristics from the first 100 patients in Germany. Br J Dermatol. 2023;188(3). doi: 10.1093/bjd/ljad162.038
   PubMedGoogle Scholar
• Chiricozzi A, Di Nardo L, Gori N, et al. Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis. Exp Dermatol. 2023;32(9):1531–1537. doi: 10.1111/exd.14859
   PubMed Web of Science ®Google Scholar
• Touhouche AT, Cassagne M, Berard E, et al. Incidence and risk factors for dupilumab associated ocular adverse events: A real-life prospective study. J Eur Acad Dermatol Venereol. 2021;35(1):172–179. doi: 10.1111/jdv.16724
   PubMed Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151. doi: 10.1016/j.jaad.2019.02.053
   PubMed Web of Science ®Google Scholar